2007
Alessandro Serretti
PHARMACOGENETICS OF ANTIDEPRESSANTS
Salud Mental, noviembre-diciembre, año/vol. 30, número 006
Instituto Nacional de Psiquiatría Ramón de la Fuente
Distrito Federal, México
pp. 1-12
Since the serendipitous discovery of imipramine, in 1957, different classes of antidepressant drugs have been used to treat depressive syndromes. Although their efficacy is well established, still 30-40% of patients do not show a significant response (>50% reduction in baseline score on the Hamilton Rating Scale for Depression – HAMD) to therapeutic doses of antidepressant medications administered for 6-8 weeks of treatment, while 60-70% fail to achieve full remission (17-item HAMD<7) (Moncrieff and Kirsch, 2005). Partial remission has been associated with a higher recurrence, a greater functional impairment and a worse quality of live (Fava et al., 2002; Tranter et al., 2002). All antidepressants have a lag phase and it takes at least 3-4 weeks to observe the real effect of treatment administration (Quitkin et al., 1996). Such a delayed response may increase the patients’ suffering and the risk of suicidal behavior and early discontinuation of treatment. Patients have to stay in hospital for longer periods and this results in higher costs. Therefore early identification of responders to a specific antidepressant treatment would be of great usefulness both from a clinical and economical point of view. Unfortunately, in spite of some evidence concerning the predictive power of demographic characteristics, illness features and social factors (Esposito and Goodnick, 2003; Goodnick, 1996; Nierenberg, 2003), none of such variables could unequivocally be linked to treatment outcome and antidepressant choice is still based on a trial and error procedure.

Inherited differences in drug response have been described for a variety of compounds supporting the influence of genetic factors on treatment outcome (Roden and George, 2002; Weinshilboum, 2003). This has been investigated in antidepressant short term treatment (O’Reilly et al., 1994; Orsini, 1987; Pare et al., 1962; Serretti et al., 1998). Further, one important determinant in treatment decision making is the occurrence of side effects, which can negatively impact compliance. This was reported to be of 40% to 90% in different studies of antidepressant drugs with an average of 65% (Cramer and Rosenheck, 1998). As the prevalence and severity of side effects follow interindividual variations, it is reasonable to hypothesize a genetic basis for drug tolerability (Murphy et al., 2003a). The present paper will review the literature concerning genetic influence on the efficacy and tolerability of antidepressants. Traditional approaches based on the analysis of candidate genes which act throughout pharmachodynamic and pharmacokinetic mechanisms are now integrated by complementary genome-wide approaches (Brown and Botstein, 1999).

**Pharmacodynamic aspects**

The monoamine hypothesis, which identifies the biological basis for depression in a deficiency of brain monoamine neurotransmitters (Schildkraut, 1965), is still considered a valid model to account for the mechanism of action of antidepressant drugs (Bondy, 2002). Increasing evidence demonstrates that monoaminergic systems and other biological systems implicated in the pathophysiology of depression such as the substance P and stress-hormone systems, have reciprocal interactions, and ultimately stimulate neurogenesis (Reul and Holsboer, 2002; Schwarz and Ackenheil, 2002). These pathways showed to be affected by several antidepressant treatments, thus they represent the main focus of pharmacogenetic research. Other lines of investigation have included inflammatory cytokines (Schiepers et al., 2005) and the endogenous clock system (Healy and Waterhouse, 2005).

**Brain monoamine systems**

*Tryptophan hydroxylase*. Tryptophan hydroxylase (TPH) catalyzes the rate-limiting step in 5-HT biosynthesis.
Its prominent role in the pathophysiology of depression is underscored by the fact that tryptophan depletion can induce a transient depressive state in individuals with a known history of depressive disorder (Booij et al., 2003). The gene encoding TPH1 has been cloned and mapped on 11p15.3-p14 (Craig et al., 1991). It includes two bi-allelic polymorphisms in position 218 (A218C) and 779 (A779C) of intron 7, which are in strong disequilibrium (Nielsen et al., 1997). The A218C polymorphism is located in a potential GATA transcription factor-binding site, therefore it may influence gene expression, and consequently antidepressant (AD) response. The rarer TPH*A-allele of A218C polymorphism showed in fact to be associated with a decreased 5-HT synthesis (Jonsson et al., 1997), even if this finding has not been replicated.

The presence of this allele may predispose to suicidal behavior as emerged from two recent meta-analyses (Bellivier et al., 2004; Rujescu et al., 2003). The A-allele was also associated with a slower and less marked HAMD improvement in two double-blind trials with fluvoxamine and paroxetine we carried out in our center in Milan (Serretti et al., 2001b; Serretti et al., 2001c). Subsequent studies performed in Japan (Yoshida et al., 2002b) and Korea (Ham et al., 2005) failed to demonstrate a correlation between the TPH A218C polymorphism and response to Selective Serotonin Reuptake Inhibitors (SSRIs). Recently a new TPH isoform was discovered and called TPH-2 (Walther et al., 2003), while the original isoform is now TPH-1.

The gene encoding TPH-2 (chromosome 12) is 150-fold more expressed in mouse brain than the TPH-1 gene (Malek et al., 2005), therefore it might represent a promising candidate for pharmacogenetic investigation. Peters et al. tested both TPH isoforms in 96 unipolar depressives patients treated with fluoxetine for 12 weeks (Peters et al., 2004). While the TPH-1 gene was associated with general response, TPH-2 variants were implicated in specific response to fluoxetine. These findings are in line with the latest published studies demonstrating that all TPH isoforms are expressed in the human brain, with different levels of each isoform between the brain areas (Zill et al., 2005). Two studies examined the relationship between TPH-2 polymorphisms and resistant depression (Garriock et al., 2005; Zhang et al., 2005): a marginal association emerged with the TPH-2 G1463A single-nucleotide polymorphism (Zhang et al., 2005).

**Serotonin transporter.** Extracellular monoamines are cleared from the synaptic cleft and carried into the synaptic terminal by plasma membrane proteins which are termed transporters. As these proteins are high-affinity targets for psychostimulants (cocaine, amphetamine) and different classes of ADs, they are suitable candidates for pharmacogenetic research. To date, a large amount of studies have involved the serotonin transporter (SERT) gene. The brain SERT is the principal site of action of many antidepressant drugs (SSRI, TCA) and mediates the behavioral and toxic effects of cocaine and amphetamines. SERT knockout mice show robust phenotypic abnormalities when compared to normal mice, with increased anxiety and inhibited exploratory locomotion (Holmes et al., 2003a). The deletion of the SERT gene produces also a reduction in aggressive behavior and home cage activity of knockout mice; this effect is further enhanced by desensitization of 5-HT1A and 5-HT1B receptors (Holmes et al., 2003b).

Ramamoorthy et al. (1993) identified and cloned a single gene encoding the human SERT (SLC6A4), localized to chromosome 17q11.1-1q12. The gene spans 31 kb and consists of 14 exons (Lesch et al., 1994). Heils et al. (1996) reported a polymorphism in the transcriptional control region upstream of the SERT coding sequence. The polymorphism is located approximately 1000 bp upstream of the transcription initiation site within a region composed of 16 repeat units (5-HTTLPR). It consists of a 44-bp insertion/deletion involving units 6 to 8. It is known that the long (l) 5-HTTLPR allele has twice the SERT expression in the basal state than the short (s) form. As the 5-HTTLPR polymorphism can affect SERT expression and SERT is the main target of SSRIs, it is reasonable to hypothesize the influence of 5-HTTLPR variants on SSRI response. This has been tested in several studies (table 1): a better outcome in l-allele carriers (Arias et al., 2003; Joyce et al., 2003; Murphy et al., 2004; Pollock et al., 2000; Rausch et al., 2002; Smeraldi et al., 1998; Zanardi et al., 2000; Zanardi et al., 2001) has been a consistent finding among Caucasian patients. Instead, Asian studies produced conflicting results, with some samples showing the same genotype-response association pattern as Caucasians (Kato et al., 2005; Lee et al., 2004b; Yu et al., 2002) and others revealing a better response in 5-HTTLPR s-allele carriers (Kim et al., 2000; Yoshida et al., 2002a) or no effect of the 5-HTTLPR (Yoshida et al., 2004). Most likely the small sample sizes, different ethnicity and different definition of responders do not allow to draw a definite conclusion on the role of the 5-HTTLPR polymorphism. This appears to influence treatment outcome independently from other predictors, including antidepressant dose and SERT affinity (Rausch et al., 2002).

Recent studies suggest that the 5-HTTLPR polymorphism may also affect antidepressant tolerability. Thus in a double-blind trial of elderly

Salud Mental, Vol. 30, No. 6, noviembre-diciembre 2007
outpatients s-allele carriers treated with paroxetine were characterized by more severe adverse effects and higher discontinuation rates compared to 1/l homozygotes, while in a subgroup on mirtazapine the s-allele was associated with a better tolerability and fewer discontinuations (Murphy et al., 2004). Still the s-allele was shown to identify patients at risk for developing insomnia and agitation with fluoxetine treatment (Perlis et al., 2003). However other studies reported no association between 5-HTTLPR variants and side effects occurring with SSRIs (Takahashi et al., 2002). Two studies demonstrated an increased risk for antidepressant-induced mania with carriage of the s-allele (Masoliver et al., 2006; Mundo et al., 2001), but negative findings were also reported (Rousseva et al., 2003; Serretti et al., 2004b).

Over the last few years new polymorphisms within the SERT gene have attracted attention as predictors of antidepressant response, their interaction with the 5-HTTLPR waiting to be elucidated. Ogilvie et al. identified a different variable number tandem repeat (VNTR) polymorphism in the second intron of the SERT gene (Stin2) which was related to susceptibility to major depression (Gutierrez et al., 1998; Ogilvie et al., 1996). Ito et al. (2002) reported no association of Stin2 with fluvoxamine response. A single nucleotide polymorphism (rs25531 SNP), located just upstream of the 5-HTTLPR, revealed a significant influence on antidepressant response to fluoxetine and, intriguingly, a moderation effect on 5-HTTLPR alleles. In the presence of the G-allele of this SNP, the l-allele of the 5-HTTLPR is associated with non-response, as the s-allele where it is expressed together with the A-allele of the rs25531 SNP (Kraft et al., 2005).

Norepinephrine transporter. One study determined whether NET gene variants could affect response to minalcipram (Yoshida et al., 2004). Significant associations were reported with the T-128C (T-allele predicting a better response) and A1287G polymorphisms (slower onset of response in A/A genotype carriers).

Monoamine oxydase A. MAO-A is a major degrading enzyme in the metabolic pathways of monoamine neurotransmitters (NE, DA, 5-HT). The gene encoding MAO-A - chromosome Xp11.23 (Sabol et al., 1998) - is supposed to influence the mechanism of action of SSRIs through an interaction with SERT (Maes and Meltzer, 1995). A polymorphism located 1.2 kb upstream the MAO-A coding sequences (VNTR) was reported to affect the transcription of the MAO-A promoter (Sabol et al., 1998). Its influence on AD treatment efficacy was investigated in three studies which yielded negative results (Cusin et al., 2002; Muller et al., 2000; Yoshida et al., 2002b). More recently, in a sample of Chinese inpatients with major depressive disorder, the 3-repeat variant of the MAO-A VNTR was positively associated with antidepressant treatment outcome in females (Yu et al., 2005).

Catechol-o-methyltransferase. COMT is involved in the catabolic pathways of NE and DA. Moreover, this enzyme can indirectly affect brain 5-HT through reciprocal interactions between DA and 5-HT. Lachman et al. (1996) reported a functional polymorphism consisting on a transition of guanine to adenine at codon 158, leading a substitution of Val to Met in MB-COMT (and in position 108 in S-COMT). It has been shown that the Met allele results in a three to fourfold lower enzymatic activity than Val allele (Mannisto and Kaakkola, 2005; Weinshilboun et al., 1999). Two recent studies report that patients with Met-Met homozygosity are less likely to respond to mirtazapine (Szegedi et al., 2005) and citalopram (Arias et al., 2006).

Beta 1 adrenerceptor. These receptors serve as important regulators of Central Nervous System-mediated behavior and of several neural functions, including mood, memory, neuroendocrine control, and stimulation of autonomic function, and are involved in the mediation of AD effects (Crisman et al., 2001). This may also explain why beta-blocker medications are associated with side effects such as depression and lethargy (Kirigiti et al., 2000).

Beta 1 adrenergic receptor gene ADRB1 was mapped on 10q24-q26 (Yang-Feng et al., 1990). A polymorphism in the intracellular cytoplasm tail, consisting of a G/C transversion at position 1165 of the ADRB1 gene, was shown to alter the receptor-Gs protein interaction, with functional consequences on signal transduction (Mason et al., 1999). This polymorphism was also found to affect response to “noradrenergic” antidepressant agents, even if the finding was only marginally significant (Zill et al., 2002).

Dopamine receptors. DA-containing neurons are located primarily in the midbrain and a number of experimental observations have suggested that a decreased dopaminergic neurotransmission might be associated with depression. Moreover, an interaction between the serotonergic and dopaminergic systems in the nucleus accumbens has been established, since motivation and hedonia have been associated with DA release in the nucleus accumbens (Zangen et al., 2001). In spite of these data suggesting a pathogenic role for the dopamine system in depressive disorders, no significant association of DRD2 and DRD4 variants with SSRI efficacy was observed in a large sample (N=364) of
depressed inpatients collected in our center in Milan (Serretti et al., 2001a).

5-HT1A receptors. These receptors are located on cortical and limbic neurons, both at postsynaptic and presynaptic levels where they act as autoreceptors, preventing the further release of 5HT with a negative feedback. Pindolol is thought to accelerate the onset of AD action by blocking 5-HT1A autoreceptors (Perez et al., 1997). A SNP in the promoter region of the 5-HT1A gene (G to C substitution at position –1019 [Wu and Comings, 1999]) was associated with the diagnosis of major depression in a case-control study (Lemonde et al., 2003) and, more recently, with antidepressant treatment outcome. Since 2004 five independent studies reported either a better response to SSRI drugs in 5-HT1A –1019G allele carriers (Hong et al., 2006) or a worse response in G-allele carriers (Kohen et al., 1996) reported a silent polymorphism consisting of a thymidine to cytosine substitution at position 267 (TC 267) within the first exon of the 5-HT6 receptor gene. This SNP was investigated for association with AD response in two studies. In the first one, 34 MDD patients receiving various ADs yielded negative results (Wu et al., 2001). More recently, in a study involving a larger MDD sample (N=71), 5-HT6 receptor CT heterozygotes were found to have a better response to AD treatment than homozygotes (CC + TT genotypes) (Lee et al., 2005).

Intracellular signal transduction pathways

G-protein Beta-3 subunit. G-proteins are key components of intracellular signal transduction in all cells of the body including neurons. Inactive G-proteins are trimers coupled with receptors on the cell-membrane. The active form is a GTP-bound alpha monomer resulting from the dissociation of a beta-gamma dimer (Neer, 1995). Chronic treatment with fluoxetine showed to attenuate GTP binding to gamma subunit in the dorsal raphe nucleus of rats, thus inducing desensitisation of 5HT1A receptors (Castro et al., 2003). Beta subunit is subdivided into three subtypes. The gene encoding beta3 subunit (GNB3) is located at human chromosome 12p13, in a region which harbours other five genes (Ansari-Lari et al., 1996). Its sequence spans 7.5 kb and includes 11 exons and 10 introns. A polymorphism in GNB3 exon 10 (C825T SNP) has been shown to modulate signal transduction and ion transport activity (Siffert et al., 1998). GNB3 825T variant is associated with the occurrence of the splice variant Gbeta3s, which, despite a deletion of 41 amino acids, is functionally active in reconstituted systems. To date, four independent studies have demonstrated a better antidepressant response in patients with one or two copies of the Gbeta3 T-allele (Joyce et al., 2003; Lee et al., 2004a; Serretti et al., 2003b; Zill et al., 2000). Hong et al. (2006) reported the only negative study in an Asian sample.

5-HT6 receptors. This is a G-protein coupled receptor which stimulates adenyl cyclase. In the rat it shows high affinity for ADs such as mianserin and clomipramine (Boess et al., 1997). 5HT6 receptor antagonists seem to improve retention performance in experimental animals which has implicated a role for 5HT6 in cognition enhancement (Meneses, 2001; Rogers and Hagan, 2001). Kothen et al. (1996) reported a silent polymorphism consisting of a thymidine to cytosine substitution at position 1019.

Stress hormone system

Stressful or traumatic events occurring in early life significantly increase the risk for depression in adulthood (Nemeroff and Vale, 2005). To further underscore the
relationship between stress response and depressive disorder, genes coding for components of the stress hormone system have so far been associated with AD treatment outcome.

**CRH receptor 1.** A number of animal studies have displayed the antidepressant properties of CHR receptor 1 antagonists (Overstreet and Griebel, 2004; Seymour et al., 2003). A three SNP haplotype within the corticotrophin-releasing hormone receptor 1 (CRHR1) could be associated with response to desipramine or fluoxetine in a sample of Mexican-Americans (Licinio et al., 2004).

**Glucocorticoid receptor gene.** A research group in Munich, Germany, identified a functional polymorphism of the glucocorticoid receptor (GR) gene (ER22/23EK) and a series of SNPs within the gene encoding the hsp90 co-chaperone FKBP5 (a part of the mature GR heterocomplex that regulates GR sensitivity), which were shown to modulate the onset of response to various classes of antidepressant drugs (Binder et al., 2004). However no replication followed.

**ACE-substance P system**

*Angiotensin converting enzyme.* There is increasing evidence pointing to the involvement of the substance P system in the pathophysiology of depression. NK1 receptor antagonists have shown preclinical activity in several paradigms of anxiety and depression (Czech et al., 2005; Gentsch et al., 2002). Mutant mice lacking the NK1 receptor gene have an increased firing rate of dorsal raphe serotonergic neurons, an effect that can also be seen after the administration of substance P antagonists (Arranz-Estevez, 2005). When given chronically, NK1 antagonists promote an enhancement of serotonergic transmission in the hippocampus that seems to be mediated by interaction with other neurotransmission systems (Guirao et al., 2006). Clinical efficacy of such drugs has also been demonstrated among patients with major depression, although the results have been inconclusive (Kramer et al., 2004). In the Central Nervous System substance P is co-localized with the angiotensin converting enzyme (ACE) which is thought to participate in its degradation. An intrinsic insertion/deletion (I/D) polymorphism determines functional variants of the ACE gene with a secondary impact on substance P levels and antidepressant activity. Indeed, the D allele, which determines higher ACE plasma levels (Rigat et al., 1990), was recently associated with higher substance P levels (Arinami et al., 1996) and a faster response to antidepressant treatments (Baghai et al., 2003), including total sleep deprivation (Baghai et al., 2003), particularly among females (Baghai et al., 2004). Interestingly, this polymorphism also influences HPA-axis reactivity in depressed patients, with patients carrying the D/D genotype having the highest cortisol response in the Dex-CRH test administered at admission (Baghai et al., 2002). More recently, another component of the ACE-substance P system, the angiotensin II receptor gene (ATI), was added to outcome predictors in major depression (Bondy et al., 2005).

**Proinflammatory cytokines**

*Interleukin 1-Beta.* Interleukin-1 (IL-1), produced mainly by blood monocytes, mediates the host reactions of acute phase response. In female rats, IL-1 may induce a behavioral complex called sickness behavior, characterized by locomotor retardation, sleep disorders, soporific effects, anorexia, weight loss, hyperalgesia, decreased social exploration, and inhibition of sexual behavior (Dantzer et al., 1998). This animal behavior, which resembles human depression, can be inhibited by chronic antidepressant treatment (Dunn et al., 2005). Increased production of IL-1 has been reported in patients with major depression and dysthymia (Anisman et al., 2002; Anisman et al., 1999). IL-1, like other cytokines, may cause hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis and reduction in 5-HT levels which ultimately result in the onset of depression (Dunn et al., 2005). The association of a biallelic polymorphism (-511C/T SNP) located in the promoter region of the IL-1beta gene to fluoxetine response was studied in 119 depressed patients who underwent a 4-week treatment with fluoxetine. Trial results showed a trend towards T/T homozygotes having milder depressive symptoms and a more favorable fluoxetine response compared to C-allele carriers (Yu et al., 2003).

**Endogenous clock system**

*Circadian Locomotor Output Cycles Kaput (CLOCK).* The endogenous control of circadian rhythms is regulated by a central pacemaker localized in the suprachiasmatic nuclei (SCN) of the anterior hypothalamus. Several genes are thought to interact in rhythms control and they are called “clock” for their function of regulation of timing in biological functions (Reppert and Weaver, 2001). In particular, CLOCK gene was identified in mice (King et al., 1997) and in humans (Steeves et al., 1999). The mRNA of human CLOCK gene has been found in the SCN, hippocampus, piriform cortex and cerebellum (Steeves et al., 1999), all areas involved in biological rhythms. One polymorphism, named 3111 T/C located in the 3' flanking region, has been shown to affect mRNA stability and half-life (Mignone et al., 2002). The C allele has been associated with significantly higher “eveningness” in healthy subjects and with a delay in preferred timing for activity or sleep episodes, with no
changes in sleep architecture (Katzenberg et al., 1998). In mood disorders the same C variant was associated with higher recurrence rates in bipolar patients (Benedetti et al., 2003), increased lifetime sleep disturbances (Serretti et al., 2003a) and persistence of insomnia during antidepressant treatment (Serretti et al., 2005).

Pharmacokinetic aspects

Cytochrome P450 enzyme complex. The cytochrome P450 (CYP) superfamily exists in over 50 isoenzymes that catalyze the oxidation of many drugs and chemicals. In humans, seven isoforms -CYP1A, CYP2A6, CYP2B6, CYP2C, CYP2D6, CYP2E1 and CYP3A enzymes- account for approximately 70% of the liver cytochromes. CYP2D6 has been implicated in the metabolism of most antidepressant drugs (Lin and Lu, 1998). So far, up to 75 different alleles have been reported for CYP2D6; more than 15 of these encode an inactive or no enzyme at all, while others consist of gene duplications (Bertilsson et al., 2002). Such gene variants have shown a clear influence on drug metabolism, and individuals are classified as poor (PM), intermediate (IM), extensive (EM) and ultra-rapid (UM) metabolizers according to their inherited genetic profile (Nebert and Dieter, 2002). However, their effect on AD response and tolerability is less consistent and still under investigation.

A direct correlation was observed between the number of functional CYP2D6 gene copies and plasma levels of some TCAs such as nortryptiline (Dalen et al., 1998). From these pharmacokinetic studies it has been extrapolated that starting doses of nortryptiline are probably enough to reach therapeutic plasma levels in subjects with no or only one functional copy of the CYP2D6 gene, among whom higher doses might increase toxicity. On the contrary, high-normal doses of the drug may be required for patients with 2-4 copies (Bertilsson et al., 2002). Dose adjustments according to CYP2D6 genotype have been proposed for TCAs in view of their small therapeutic “windows” (Kirchheiner et al., 2001).

Like TCAs, CYP2D6 variants have been shown to modify the plasma concentrations of the SSRI paroxetine (Oezdemir et al., 1999) and the SNRI venlafaxine (Veeckind et al., 2000). For the latter, a relationship between PM status and the increased occurrence of cardiovascular side effects or toxicity has been reported. On the contrary, no relationship between CYP2D6 genotype, tolerability and efficacy was observed in a sample of geriatric inpatients on paroxetine (Murphy et al., 2003b). So, even if dose recommendations based on CYP2D6 genotypes have been put forward for SSRIs too, the relevance of such dose adjustments is questionable given their flat dose response curve (Brosen and Naranjo, 2001). The impact of CYP2D6 variants might be greater for SSRI + TCA combined treatments. Indeed, co-administration of paroxetine and desipramine in EM who had at least two functional copies of the CYP2D6 gene was found to result in a 5-fold decrease in desipramine clearance (Brosen et al., 1993).

P-glycoprotein. P-glycoprotein is a member of the highly conserved superfamily of ATP-binding cassette (ABC) transporter proteins. It acts as a pump that, in view of its localization –liver, kidney and small capillars of the blood-brain barrier (Thiebaut et al., 1987)–, appears to regulate the clearance of xenobiotics and access to the brain for psychotropic drugs (Schinkel et al., 1996). The gene encoding p-glycoprotein –formerly MDR1, now ABCB1– is localized to chromosome 16. An intrinsic ABCB1 polymorphism was found to be associated with remission to antidepressant therapy but not with drug plasma levels (Uhr, 2005). It is therefore likely that ABCB1 variants influence antidepressant response by affecting the transport of drugs across the blood-brain barrier, with a mechanism that does not imply modification of drug plasma concentration.

Perspectives in psychopharmacogenetics

In spite of the popular claim that pharmacogenetics holds promises for an individualized approach to psychopharmacology, important shortcomings have so far hampered the use of research data in clinical practice:

1. Although the literature provides us with an increasing number of candidate genes, only a few of them could be consistently associated with drug efficacy or tolerability.
2. Even those genes with a proven influence on drug behavior could show opposite effects in different studies.
3. Only a small amount of variance in individual response to psychotherapeutic drugs could be explained by genetic factors.

Accordingly, improving the consistency of results across studies and expanding the number of candidate genes appear to be priorities in the agenda of today’s psychopharmacogenetics.

In the study of clinical response, focus is classically decreasing in overall psychopathology. However, increasing evidence suggests that single candidate genes can have a selective impact on few clusters of symptoms rather than on the global clinical pictures of mood disorders. For instance, the therapeutic effect of 5-HTTLPR variants is principally directed to somatic anxiety (Kato et al., 2005; Yu et al., 2002). Similarly, the C/C genotype of the CLOCK gene was associated with persistence of insomnia during SSRI treatment, while it
had no effect on overall antidepressant response (Serretti et al., 2005). This may imply that a major cause of contrasting findings in published studies is the presence of different symptom profiles in their samples. So, future pharmacogenetic analyses should target symptom dimensions.

Each candidate gene may also be related to factors that independently affect treatment outcome. For example, as personality traits and disorders are known to worsen the outcome of treated mood disorders, genes that are associated with these factors should predict a poor drug response. Accordingly, recent studies demonstrate an excess of anxiety traits in the presence of the 5-HTTLPR s-allele (Lesch et al., 1996; Melke et al., 2001), which was already linked with a negative prognosis of antidepressant treatment (see above). Most findings in the field of pharmacogenetics could be obtained by exploring a relatively small number of candidate genes which encoded proteins involved in drug activity. In spite of some appreciable results, this hypothesis-driven approach is probably too restrictive and leaves out a large number of candidate polymorphisms. Indeed, all observed gene variants do not reach the putative 50% of variance explained by genetic factors in the complex trait of antidepressant response. Pharmacogenomics may then aid in identifying more candidates by discovering those genes that are activated or de-activated in response to treatment (Bailey et al., 1998). One popular method of experimental genomics is expression array (Brown and Botstein, 1999). This involves hybridization of fluorescent or radioactively labeled mRNA species to cDNA arrays. So, thousands of mRNA transcripts are analyzed by pooling together such different features on individuals. Complex phenotypic profiles will then be obtained by pooling together such different features on the basis of their linear association with gene variants (Serretti et al., in press). This is a simple methodology to resume solitary data in comprehensive models, and we suggest it as a starting-point for future research on the role of crucial genes in modulating human behaviors.

Besides individualizing drug treatment, pharmacogenetics/pharmacogenomics would offer a good solution to the problem of biological diversity in psychiatric disorders. Thus, response to a given drug could be used to identify homogeneous forms within pathophysiologically heterogeneous syndromes, which may facilitate the discovery of new susceptibility genes for psychiatric conditions. This strategy has been proposed and successfully applied to lithium response in bipolar disorder (Alda, 1999). However, the emerging literature has extended the influence of single genes to a wide range of psychological and psychopathological phenomena in addition to drug response. The SERT gene is an emblematic example of such multiple effects. Indeed, the 5-HTTLPR polymorphism has been associated with different characteristics of mood disorders: age of onset (Bellivier et al., 2002; Nobile et al., 2004), illness recurrence (Cusin et al., 2001; Rousseva et al., 2003), drug response (see above), reactivity to stressful life events (Caspi et al., 2003), personality traits (Park et al., 2004) and several psychiatric diagnoses such as alcoholism (Feinn et al., 2005), smoking (Kremer et al., 2005), psychosomatic disorders (Yeо et al., 2004), eating disorders (Matsushita et al., 2004; Steiger et al., 2005), suicide (Courtet et al., 2001), autism (Bartlett et al., 2005) and attention deficit hyperactivity disorder (Bobb et al., 2005). Future studies will clarify whether such phenotypes are all simultaneously present or at different times in the same individuals. Complex phenotypic profiles will then be obtained by pooling together such different features on the basis of their linear association with gene variants (Serretti et al., in press).

**REFERENCES**


158. UHR M: ABCB1 genotyping is crucial for treatment with drugs that are P-glycoprotein substrates. *Biol Psychiatry*, 57:785, 2005.


